Using real-world patient experiences to inform point-of-care decisions and care management strategies in urothelial carcinoma.

Authors

null

Tariqa Ackbarali

PlatformQ Health Education, Needham, MA

Tariqa Ackbarali, Stephanie Chisolm, John L. Gore, Joshua J Meeks, Neal D. Shore

Organizations

PlatformQ Health Education, Needham, MA, Bladder Cancer Advocacy Network, Bethesda, MD, Department of Urology, University of Washington, Seattle, WA, Jesse Brown VA Medical Center, Chicago, IL, Carolina Urologic Research Center, Myrtle Beach, SC

Research Funding

Pharmaceutical/Biotech Company
Merck; Astellas and Seagen Inc.; and UroGen Pharma, Inc.

Background: Approvals of targeted therapies and immune checkpoint inhibitors hold the promise of improving long-term survival in patients with urothelial carcinoma. Competence gaps that were identified prompted the design of a unique educational series for the urology-oncology team. Optimal management of urothelial carcinoma relies on effective patient-provider communication and decision-making. To provide an integrative learning experience, the patient voice was embedded into the clinical content through shared insights and patient-reported data. Methods: A 4-part CME series was launched live-online in October 2021 in partnership with the Large Urology Group Practice Association and remains on-demand through October 2022 at UroCareLive.com and OMedLive.com. A companion patient program was held in September 2021 in partnership with the Bladder Cancer Advocacy Network and remains on-demand at CancerCoachLive.com. Behavioral assessment of preferences and attitudes toward managing patients were examined throughout the CME series and patient/caregiver program. A planned analysis of the data from these questions will determine patient and clinical impact. Outcomes from the patient program were analyzed and presented during the CME series followed by expert-identified strategies to improve clinical practice. Results: To date, 775 clinicians and 15,193 patients have participated in the educational initiative. Of the patient-reported experiences and preferences: 44% prefer to discuss benefits and risks of treatment options; and while 85% prefer to make decisions with their team, 67% felt overwhelmed and ultimately allowed their team to select therapy. Patient insights revealed challenges related to quality of life, side-effect management, and disease management. Patient-provider disparities were observed across preferences for point-of-care treatment discussions and quality of life challenges. Clinical and patient impact following integration of the patient voice will be analyzed. Conclusions: The initiative contributed to the provision of valuable patient insights and preferences based on real-world experience which were integrated into provider education. Increasing this awareness fostered practical strategies and discussion to improve patient-centered care. Education incorporating the patient voice into provider education can further sensitize clinicians to patient concerns and facilitate point-of-care decision-making.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience

Sub Track

Integrating Patient Experience Assessment and Patient Reported Outcomes Into Practice

Citation

J Clin Oncol 40, 2022 (suppl 28; abstr 280)

DOI

10.1200/JCO.2022.40.28_suppl.280

Abstract #

280

Poster Bd #

G19

Abstract Disclosures